CHICAGO (PRWEB) October 01, 2018
Paragon Biosciences CEO Jeff Aronin was recently recognized by Insights Care magazine for his innovative leadership in the biosciences sector and for his work bringing life-altering drugs to patients in need. Jeff’s vision has led Paragon to the top of the industry with over 32 Novel and New Drug Approvals earned by the R&D teams now at Paragon and its portfolio companies.
From his inspiration as a young professional to his role as a leading industry executive, Insights Care highlighted how Jeff “strived to merge his work with his passion for bringing innovative therapies to people living with severe conditions with high unmet medical need.” For his core therapeutic areas including neurology, Jeff Aronin’s pharmaceutical companies have earned more NDA approvals than any other company during the past 10 years, including the largest pharmaceutical companies in the world.
“From my earliest days, the opportunity to meet with patients and physicians and hear their stories always reminded me that the work we’re doing really makes a difference,” Jeff told the magazine. That work ultimately led to his founding of Paragon Biosciences, described by Insights Care as “a pioneer in venture innovation” that “invests in and incubates high-growth biotechnology companies.”
Since October 2017, Paragon has invested over $450 million in pharmaceutical compounds and built high growth biopharmaceutical companies aimed at directly at developing treatment for those in need.
Paragon’s portfolio companies include Castle Creek Pharma, Harmony Biosciences, Skyline Biosciences and Emalex Biosciences, and are committed to finding treatments for patient needs not addressed by larger pharmaceutical companies. Jeff notes that, while the FDA approval process can be arduous, Paragon’s model works because it is based on a “focused strategy that puts patients first and addresses true unmet needs.” Paragon plans to continue investing in this vision through over $445 million in planned capital deployment in the next 12 months.
Jeff credits his success to key leadership principles, including his ability to recruit and maintain a team committed to the same vision. In fact, many of his staff have stayed with him for over 15 years. “Our scientists are putting in years of dedication into research, and there are many patients who desperately need these medications,” Jeff told the magazine.
Despite the taxing persistence needed to achieve the success realized by Jeff and Paragon, the company’s leader told the magazine “the most rewarding thing is when you hear that a drug you brought to market is improving or saving someone’s life.”
The full article can be found here: https://insightscare.com/jeff-aronin-innovative-entrepreneur-putting-patients-first/
About Paragon Biosciences
Paragon Biosciences, LLC improves the lives of patients suffering from debilitating diseases by building innovative biotechnology companies which bring important treatments to the market. Paragon's portfolio companies are managed by healthcare industry leaders and biotech entrepreneurs committed to improving outcomes for patients. Paragon's leadership and management team leverage their entrepreneurial experiences and their expertise to develop and finance biotechnology companies and accelerate their advancements. Paragon Biosciences is headquartered in Chicago, Illinois. For more information, visit: http://www.paragonbiosci.com